Idelalisib in a patient with refractory Waldenström’s macroglobulinemia complicated by anuric renal failure: a case report
Abstract Background Waldenström’s macroglobulinemia is a rare B-cell lymphoma. The gold standard treatment for Waldenström’s macroglobulinemia is an anti-CD20 antibody (rituximab) in combination with alkylating agents and dexamethasone. Treatment targeting the B-cell receptor such as ibrutinib (but...
Main Authors: | M. D’Aveni-Piney, M. Divoux, H. Busby-Venner, M. Muller, J. Broséus, P. Feugier |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-06-01
|
Series: | Journal of Medical Case Reports |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13256-018-1694-z |
Similar Items
-
Unusual presentation of Waldenstrom macroglobulinemia
by: Chih-Yu Chang, et al.
Published: (2018-03-01) -
Good Profile of Efficacy/Tolerance of Bortezomib or Idelalisib in Waldenström Macroglobulinemia Associated with Acquired Von Willebrand Syndrome
by: Ojeda-Uribe M, et al.
Published: (2020-02-01) -
Membranoproliferative glomerulonephritis complicating Waldenström’s macroglobulinemia
by: Kratochvil David, et al.
Published: (2012-12-01) -
Splenic re-irradiation for waldenstrőm’s macroglobulinemia
by: Wei Zhou, et al.
Published: (2012-04-01) -
Macroglobulinemia de Waldenström - remissão completa após tratamento com rituximabe Successful outcome in Waldenström's macroglobulinemia treated with rituximab
by: Flavia C. F. Pimenta, et al.
Published: (2008-10-01)